Vialox vs PNC-27
Side-by-side comparison of key properties, dosing, and research.
- Summary
- Vialox is a synthetic pentapeptide that mimics the activity of conotoxin from cone snails, acting as an antagonist of nicotinic acetylcholine receptors at the neuromuscular junction. Similar to Syn-Ake but derived from cone snail venom biochemistry, it reduces facial muscle contraction to smooth expression wrinkles.
- PNC-27 is a synthetic peptide derived from the p53 tumor suppressor protein, containing both an HDM2-binding domain and a transmembrane penetratin sequence. It selectively kills cancer cells by binding MDM2/HDM2 overexpressed on the plasma membrane of malignant cells, inducing membranolysis without harming normal cells.
- Half-Life
- Not applicable (topical; effect duration hours)
- Not well established; estimated minutes to hours
- Admin Route
- Topical
- Intravenous (research), Intraperitoneal (research)
- Research
- —
- —
- Typical Dose
- 0.005-0.05% in formulation
- Not established for humans; research doses vary by cell line and model
- Frequency
- Twice daily
- Not established for human use
- Key Benefits
- Reduces dynamic wrinkles from repetitive facial expressions
- Reversible muscle-relaxing effect without injection
- Smooths forehead, periorbital, and perioral lines
- Complementary to collagen-stimulating peptides
- Well-studied tolerability in cosmetic concentrations
- Can be combined with Syn-Ake for dual conotoxin/viper venom effect
- Selective cytotoxicity against cancer cells overexpressing HDM2/MDM2
- Spares normal cells lacking surface HDM2 expression
- Membranolytic mechanism bypasses intracellular resistance pathways
- Demonstrated activity against breast, pancreatic, leukemia, and melanoma cell lines
- Potential for combination with conventional chemotherapy
- Novel non-genotoxic anticancer mechanism
- Side Effects
- Generally very well-tolerated topically
- Rare contact sensitivity or mild irritation
- No clinically significant systemic neuromuscular effects at cosmetic doses
- Limited human clinical data; largely in vitro and animal studies
- Potential immunogenic reactions (foreign peptide)
- Systemic toxicity at high doses not well characterized
- Unknown interactions with current chemotherapy agents
- Stacks With
- —
- —